doi: 10.1161/hq1101.098552
© 2001 American Heart Association, Inc.
Vascular Biology |
Localization of c-Myb and Induction of Apoptosis by Antisense Oligonucleotide c-myb After Angioplasty of Porcine Coronary Arteries
From the Cardiovascular Research Group (D.L.L., L.S., J.G., S.E.F., A.K., D.C. Crossman, D.C. Cumberland), Division of Clinical Sciences, University of Sheffield, Sheffield, UK, and the Unit of Cardiac Physiology (N.M., C.M.H.), Stopford Building, University of Manchester, Manchester, UK.
Reprint requests to Dr C.M. Holt, Unit of Cardiac Physiology, University of Manchester, 1.305 Stopford Building, Oxford Road, Manchester M13 9PT, UK. E-mail cathy.holt{at}man.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—— Previous studies have shown that inhibition of the proto-oncogene c-myb inhibits neointimal formation in various animal models. However, the temporal and spatial expression of c-Myb in the vessel wall after injury is not known, and the mechanism of action of antisense oligonucleotide (AS-ODN-c-myb) inhibition remains unclear. One potential effect of cell cycle dysregulation by inhibition of c-myb is an increase in the rates of apoptosis. In this study, c-Myb expression after percutaneous transluminal coronary angioplasty (PTCA) injury and induction of apoptosis after AS-ODN-c-myb treatment were determined. Immunohistochemistry and cellular phenotyping were used to localize c-Myb expression in porcine coronary arteries at various time intervals after PTCA. In vitro, the effects of AS-ODN-c-myb on the apoptosis of porcine vascular smooth muscle cells (PVSMCs) and endothelial cells were determined by using a cell-death ELISA and time-lapse video microscopy. In vivo, local delivery of AS-ODN-c-myb was performed after PTCA of pig coronary arteries, and apoptosis was quantified at 6 hours. c-Myb is induced in pig coronary arteries after angioplasty, with maximal expression in inflammatory cells at 18 hours and in vascular smooth muscle cells at 3 to 7 days. In vitro, AS-ODN-c-myb enhanced PVSMCs (6.8±0.8% [P=<0.001] versus 0.5% serum) but not endothelial cell apoptosis (1.4±0.5% [P=NS] versus 0.5% serum). In vivo, 6 hours after porcine coronary angioplasty and delivery of AS-ODN-c-myb, the proportion of apoptotic cells within the media was 4.2±0.8% (PTCA alone), 2.3±0.2% (PTCA+vehicle), and 9.0±1.1% (PTCA+AS-ODN-c-myb; P<0.05 versus PTCA alone and P<0.01 versus PTCA+saline). c-Myb is expressed after PTCA of pig coronary arteries, and AS-ODN-c-myb induces apoptosis of PVSMCs in vitro and medial cells in vivo.
Key Words: angioplasty • proto-oncogenes • antisense • apoptosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Restenosis remains a major clinical problem after percutaneous transluminal coronary angioplasty (PTCA).1–3 Restenosis is the result of intimal hyperplasia, elastic recoil, and vessel wall remodeling.4 Vascular smooth muscle cell (VSMC) migration, proliferation, inflammation, and extracellular matrix deposition all contribute to intimal hyperplasia.5–8 In addition, as well as proliferation, apoptosis has been identified in human and experimental restenosis, and together, these processes are important in the regulation of neointimal hyperplasia.9–12
The proto-oncogene c-myb is a transcription factor, originally described as a hematopoietic factor, with roles in cell proliferation and differentiation as well as apoptosis.13–17 An important role for c-Myb is its function as a progression factor at the G1-S boundary, and expression of the proto-oncogene c-myb is also necessary for proliferation of VSMCs.13,18 We have previously demonstrated upregulation of mRNA for c-myb in a porcine coronary angioplasty model, with peak expression 18 hours after PTCA.19 In addition, we and others have shown that antisense oligonucleotide to c-myb (AS-ODN-c-myb) reduces porcine VSMC (PVSMC) proliferation in vitro19,20 and neointimal hyperplasia in vivo.18,19,21 In another study, AS-ODN-c-myb was seen to reduce proliferation as assessed by determination of proliferating cell nuclear antigen–positive cells 7 days after local delivery to pig carotid arteries22; thus, AS-ODN-c-myb has been assumed to exert its in vivo effects via cell-cycle dysregulation, resulting in reduced rates of proliferation. However, it is now known that cell-cycle dysregulation may under certain circumstances, and especially when proliferation is the background driving force, result in apoptosis.23 Induction of apoptosis after c-myb dysregulation has been suggested by Piacentini et al14 and Schmitt et al,24 who demonstrated that transfection of rat, rabbit, and human VSMCs with dominant-negative c-myb gene constructs caused not only a decrease in proliferation but also induced apoptosis. Therefore, inhibition of c-Myb induces apoptosis, and this may subsequently reduce neointimal hyperplasia; however, this possible mechanism of action of AS-ODN-c-myb has not previously been investigated.
Therefore, the aims of the present study were as follows: (1) to determine the temporal and spatial distribution of c-Myb after PTCA in a pig coronary artery model, (2) to determine whether AS-ODN-c-myb induced apoptosis of vascular cells in vitro, and (3) to determine whether modulation of apoptosis occurs in vivo after local delivery of AS-ODN-c-myb to porcine coronary arteries.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
An expanded version of Methods can be accessed at http://atvb.ahajournals.org.
Porcine Coronary Angioplasty Model
Porcine coronary angioplasty was performed according to an appropriate UK home office license by using methods previously described by Gunn et al.19 The hearts were explanted at varying time intervals, and the angioplastied arteries were excised and processed as previously described by Malik et al.10 Arterial blocks showing maximum balloon injury, defined as maximum disruption in the internal elastic lamina as evidence of injury, were selected for further analysis.25,26
Immunohistochemistry for c-Myb
c-Myb immunostaining was performed on transverse paraffin sections of control and angioplastied pig coronary arteries obtained at various different time intervals after the procedure. Positive immunostaining for c-Myb was semiquantified by using a grading system from 0 to +++.27 The region of trauma was defined as the cross-sectional area of the artery adjacent to the breached internal elastic lamina, including remnants of the media, adventitia, and loose connective tissue.10 The specific cell phenotype expressing c-Myb was identified by double immunostaining for c-Myb together with a phenotypic marker.
Determination of Apoptosis
Apoptosis was determined in PVSMCs and pig aortic endothelial cells (PAECs) in vitro by using cell-death ELISA and time-lapse video microscopy (TLVM). Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) was performed on histological sections of angioplastied pig coronary artery as previously described.10
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Time Course of c-Myb Expression
Western analysis revealed a single band at 75-kDa molecular mass against pig thymus, thus indicating specificity of this antibody for porcine c-Myb. In control uninjured arteries, very low levels of immunopositivity for c-Myb was identified within the media and adventitia (Figure 1A, Table). At later time points, when visible, positive staining for c-Myb was characterized by brown nuclear staining (Figure 1B and 1C). One and 6 hours after PTCA, positive staining for c-Myb was observed within the adventitia, and this appeared to localize within regions containing an inflammatory infiltrate (Figure 1D). At 18 hours, strong positive staining was detected within the media, and adventitial immunostaining was still observed in regions with an inflammatory infiltrate. Three days after injury, adventitial staining was more pronounced, and c-Myb staining was detected in microvascular endothelium and adjacent inflammatory cells (Figure 1E). Luminal endothelial and neointimal cells, when present, also expressed c-Myb. At 7 days, the staining pattern was similar to the 3-day specimens, with c-Myb staining present within the media and neointima (Figure 1B and 1C) and
-actin–positive cells within the adventitia. At 14 days, the distribution of c-Myb was similar to that at 7 days but was less intense, and at 28 days, minimal c-Myb staining was observed.
|
|
Colocalization of c-Myb With Phenotypic Markers
At 6 hours, c-Myb that was colocalized mainly within inflammatory cells was localized within areas of media and overlying thrombus at sites of trauma and within the adventitia (Figure 1D). Cell types that were not stained with the phenotypic markers used were also positive for c-Myb. These may have been fibroblasts. At 18 hours, colocalization of c-Myb with inflammatory cell phenotype was still evident, and in addition, positive cells were also identified within the media, where colocalization with -actin was seen (Figure 1F). Maximal VSMC c-Myb expression was identified at 3 to 7 days (Figure 1B and 1C), and at these time points, c-Myb was also detected within adventitial microvascular endothelium (Figure 1E). At 7 days, the adventitial cells expressing c-Myb were now -actin positive. At 28 days, minimal c-Myb expression was detected; therefore, colocalization experiments were not performed.
Cell Isolation
In vitro PVSMCs displayed smooth muscle cell morphology and were stained positively for -smooth muscle actin. PAECs showed cobblestone morphology when confluent and were -smooth muscle actin negative and DBA-lectin positive.
Time-Lapse Video Microscopy
Viewed by TLVM over 24 hours, a percentage of PVSMCs showed morphological features characteristic of apoptosis, including membrane blebbing, cell shrinkage, nuclear condensation, and detachment (data not shown). The apoptotic index, derived from TLVM, was 1.8±0.3% in 0.5% serum (n=12, Figure 2). The apoptotic index of AS-ODN-c-myb–treated PVSMCs was 6.8±0.8% (P<0.001 versus 0.5% serum, n=6). The sense-treated PVSMC apoptotic index was 2.2±0.3% (P=NS versus 0.5% serum, n=6). Thus, AS-ODN-c-myb increased apoptosis 3.8-fold over 0.5% serum and 3.1-fold over sense-treated controls. PAEC apoptotic indices were 1.4±0.2% for 0.5% serum and 1.4±0.5% for AS-ODN–treated cells (P=NS, n=6; Figure 2).
|
Cell-Death ELISA
Untreated PVSMCs in 0.5% serum had an apoptotic enrichment factor over the 5% serum "no death" control of 3.2±0.5. Sense-treated PVSMCs showed similar results: 2.8±0.4 (P=NS versus 0.5% serum, n=6; Figure 3). AS-ODN-c-myb treatment increased the apoptotic enrichment factor to 7.5±0.8 (P<0.005 versus 0.5% serum and sense SN-ODN, n=6). This represented a 2.4-fold increase over 0.5% serum–treated cells and 2.7-fold increase over SN-ODN-c-myb–treated cells. Staurosporine treatment of PVSMCs, used as a positive control, induced death of all cells by 8 hours, as determined by light microscopy, with an apoptotic enrichment factor of 41.2±1.1 (n=3). In contrast to PVSMCs, there was no significant effect of apoptosis on PAECs, after treatment with either AS-ODN (0.8±0.1 [fold increase over 0.5% serum–treated cells]) or SN-ODN (0.7±0.2%, n=6; both P=NS; Figure 3).
|
TUNEL Assay
Control vessels with no angioplasty showed very few TUNEL-positive cells with a labeling index of 0.5%. Cells were considered apoptotic only when they showed TUNEL-positive staining and the morphological characteristics of apoptosis, such as nuclear condensation and cytoplasmic shrinkage. Negative control slides without TdT enzyme showed no TUNEL-positive cells (Figure 4A). Cells were classified as medial if they were located within the internal and external elastic laminae. The majority of apoptotic cells were detected within the media and, to a lesser extent, within the adventitia (Figure 4B). At 6 hours after angioplasty, when the whole artery (ie, intima, media, and adventitia) was analyzed, the percentage of apoptotic cells was 5.0±1.1% for PTCA alone, 2.4±0.6% for PTCA+vehicle, and 6.9±1.1% for PTCA+AS-ODN-c-myb (P=NS versus PTCA alone and P<0.05 versus PTCA+saline; Figure 5). Within the media alone, the proportion of apoptotic cells was 4.2±0.8% for PTCA alone, 2.3±0.2% for PTCA+vehicle, and 9.0±1.1% for PTCA+AS-ODN-c-myb (P<0.05 versus PTCA alone, P<0.01 versus PTCA+saline; Figure 5).
|
|
Colocalization of TUNEL With c-Myb and Phenotypic Markers
Colocalization experiments revealed that a proportion of cells that were positive for mac-387 were also TUNEL positive (Figure 4C and 4D). When present, very occasional apoptotic cells were detected within the endothelium, as indicated by double staining for TUNEL and von Willebrand factor antigen (Figure 4E). However, the majority of TUNEL-positive cells were -actin positive, although not all medial VSMCs were TUNEL positive.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study has demonstrated that c-Myb protein is absent in normal pig coronary arteries but is induced after PTCA, with expression occurring at 6 to 18 hours in the media and adventitia and particularly in regions of inflammatory infiltration. Peak expression was at 3 to 7 days within
-actin–positive cells and returned to basal levels by 28 days. Furthermore, inhibition of c-Myb with the use of AS-ODN-c-myb increased PVSMC apoptosis in vitro 
3-fold. In contrast, there was no effect of SN-ODNs on PVSMCs in vitro. AS-ODN-c-myb did not alter the apoptosis of PAECs in vitro. In vivo, local delivery of AS-ODN-c-myb increased apoptosis 2-fold at 6 hours after angioplasty within the media and, to a lesser extent, within the adventitia of pig coronary arteries.
Temporal and Spatial Distribution of c-Myb
Because the peak of vascular cell apoptosis occurs at 6 hours and proliferation after balloon injury occurs at 3 days,10 a temporal association between the rise of c-Myb levels (which begins 6 hours after injury) and these processes has been established, and it is possible that c-Myb plays a role in determining the balance between cell proliferation and apoptosis occurring in the vessel wall after angioplasty. The majority of c-Myb was localized within the media and adventitia, with localization at areas of trauma within inflammatory cells and VSMCs. Early inflammation was localized to areas of trauma as previously described.10 At 7 days after injury, -actin–positive cells were identified within the adventitia. Other investigators have described this phenomenon of adventitial cells expressing smooth muscle cell characteristics, and it has been suggested to occur as a response to injury of the vessel wall.28 Previous work by our own group has shown that the transport catheter is capable of delivering AS-ODNs to the media and, to a lesser extent, to the adventitia of pig coronary arteries. Thus, delivery of AS-ODN-c-myb with use of this device would be targeted to regions of c-Myb expression.
Inhibition of c-Myb and Apoptosis In Vitro
It is known that cell cycle dysregulation may lead to apoptosis,23 and recent evidence suggests a role for c-myb in the control of apoptosis. AS-ODN-c-myb, antigenes, and dominant-negative c-myb constructs have all been shown to increase apoptosis in various cell lines.14–16 Recently, Schmitt et al24 showed a reduction in rat and rabbit VSMC proliferation and induction of apoptosis in vitro after exposure to c-myb dominant-negative constructs, supporting the findings of the present study, in which AS-ODN-c-myb induced apoptosis of porcine VSMCs. In contrast, apoptosis of PAECs was not enhanced, indicating that as previously suggested, cell fate is modulated in a cell type–specific manner.29 In addition, it suggests that endothelial cells may be spared and that early regrowth may occur after AS-ODN-c-myb treatment in vivo, with beneficial effects on arterial healing after PTCA.
Inhibition of c-Myb and Apoptosis In Vivo
Antisense oligonucleotides to c-myb have been used to inhibit neointimal hyperplasia after PTCA in a number of animal models.19,21 Given the well-characterized involvement of c-myb in VSMC proliferation and the in vitro antiproliferative effect of AS-ODN-c-myb, it was previously assumed that the in vivo effects of AS-ODN-c-myb occurred via inhibition of VSMC proliferation; however, the data obtained in the present study suggest that they may also modulate early events, such as apoptosis. Several authors have postulated that the delivery of agents that modulate apoptosis after PTCA may inhibit neointimal formation and restenosis. Indeed, Pollman et al30 demonstrated that antisense to bcl-x (antiapoptotic) mRNA after PTCA increased apoptosis 4-fold and resulted in a 50% decrease in lesion size at 7 days. Our data support the effects of increasing apoptosis after angioplasty, localized to mainly VSMCs and also inflammatory cells and very occasionally to endothelial cells, on the reduction of neointima. Interestingly, a recent clinical trial (Investigation by the Thoraxcenter on Antisense DNA given by Local Delivery and Assessed by Intravascular Ultrasound after Coronary Stenting [ITALICS]) showed that local delivery of AS-ODN-c-myc did not reduce in-stent restenosis.31 One explanation for this may be the fact that c-Myc tends to be proapoptotic; therefore, its inhibition would tend to reduce apoptosis.32 Conversely, the present study has shown that inhibition of c-myb induces apoptosis; therefore, use of AS-ODN-c-myb in the clinical setting may be more beneficial than AS-ODN-c-myc.
Study Limitations
The modest level of apoptosis induced by AS-ODN-c-myb could actually be higher in atheromatous lesions, because these cells may be more sensitive to apoptotic signals.33 Thus, the 2-fold increase shown in our porcine coronary model may underestimate the effects that could occur clinically. Furthermore, it is possible that increased apoptosis may not be of benefit in such lesions because it may lead to an increased incidence of plaque rupture and thrombogenicity of lesions.34 It is also possible that AS-ODN-c-myb may affect the duration of apoptosis that occurs after angioplasty in the pig, and later time points would be required to investigate this. However, AS-ODNs are known to have a short half-life in vivo because of their rapid breakdown by nucleases.35 For that reason, vessels were analyzed at 6 hours after PTCA; however, previous work by our group has demonstrated that local delivery of AS-ODN-c-myb via the transport catheter reduces neointimal hyperplasia in pig coronary arteries at 28 days.19
It has previously been demonstrated that heparin inhibits DNA synthesis and that this is associated with a reduction in c-Myb mRNA levels. Because heparin was used as an anticoagulant in the in vivo experiments performed in the present study, these findings may be of relevance. The present study and a previous study by our group19 have demonstrated upregulation of c-Myb in angioplastied vessels, with all procedures performed in the presence of heparin. Therefore, it is unlikely that the dose of heparin used in the present study is interfering with the observations made.
In the present study, in vitro studies were performed on pig aortic VSMCs, whereas in vivo studies used coronary arteries. However, it has recently been suggested that coronary artery smooth muscle cells exhibit unique structural and functional characteristics.36 In addition, cell heterogeneity may include the presence of VSMC subpopulations with unique differentiation patterns that may affect their susceptibility to apoptosis.37 However, the in vitro findings obtained in the present study have been validated in vivo, thus suggesting that induction of apoptosis via c-Myb antisense occurs independently of vascular tissue type.
Some studies have suggested that AS-ODN-c-myb may exert nonspecific effects. The AS-ODN-c-myb used in the present study has previously been shown by our group to reduce c-myb mRNA and protein levels with no effect on other proto-oncogene mRNA levels.19 Furthermore, S1 nuclease digestion, performed in our previous study, demonstrated the binding of ODNs to nucleic acid.19 Thus, the effects demonstrated in the present study are likely to be due to specific rather than nonspecific ODN effects. In addition, the ODN used was unmodified, thus decreasing the possibility of nonspecific binding as a result of phosphorothioation.38
Summary and Conclusions
In conclusion, the present study has demonstrated, for the first time, expression of c-Myb protein after balloon injury of pig coronary arteries, its time course of expression, location within the vessel wall, and specific cellular source. In addition, the present study suggests a new mechanism of action at the cellular level for AS-ODNs targeting c-myb in vascular cells. Tissue homeostasis involves a balance between cellular proliferation and apoptosis. During the healing response after vascular injury, these interactions will be modified. AS-ODN-c-myb is well documented to modulate VSMC proliferation. In the present study, we have reported that AS-ODN-c-myb increases PVSMC apoptosis in vitro, and in a porcine coronary balloon angioplasty model, apoptosis is induced in vivo after local delivery of AS-ODN-c-myb.
|
Acknowledgments |
|---|
The financial support of the British Heart Foundation and the expert assistance of Nadine Arnold with the care of the animals used in this study are gratefully acknowledged. Darren Lambert, who performed the majority of the work described in this study, died January 13, 2001, during submission of the manuscript for publication. He is sadly missed by his friends and colleagues.
|
Footnotes |
|---|
Darren Lambert died January 13, 2001. 
Received March 27, 2001; accepted August 22, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Kent KM. Restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1988; 61: 67G–70G.[Medline] [Order article via Infotrieve]
2. Holmes DR, Vlietstra RE, Smith HC, Vetrovec GW, Kent M, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, et al. Restenosis after PTCA: a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984; 53: 77C–81C.[Medline] [Order article via Infotrieve]
3.
Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA; Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time related phenomenon. Circulation. 1988; 77: 361–371.
4.
Glagov S. Intimal hyperplasia, vascular remodeling, and the restenosis problem. Circulation. 1994; 89: 2888–2891.
5. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992; 19: 267–274.[Abstract]
6. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994; 24: 1398–1405.[Abstract]
7.
Rogers C, Welt FGP, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996; 16: 1312–1318.
8.
Chamberlain J, Gunn J, Francis SE, Holt CM, Crossman DC. Temporal and spatial distribution of IL-1ß in balloon injured porcine coronary arteries. Cardiovasc Res. 1999; 44: 156–165.
9.
O’Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993; 73: 223–231.
10.
Malik N, Francis SE, Holt CM, Gunn J, Thomas GL, Shepherd L, Chamberlain J, Newman CMH, Cumberland DC, Crossman DC. Apoptosis and cell proliferation after porcine coronary angioplasty. Circulation. 1998; 98: 1657–1665.
11. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995; 147: 267–277.[Abstract]
12. Bochaton-Piallat M, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995; 146: 1059–1064.[Abstract]
13.
Brown KE, Kindy MS, Sonenshein GE. Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J Biol Chem. 1992; 267: 4625–4630.
14. Piacentini M, Raschella G, Calabretta B, Melino G. C-myb down regulation is associated with apoptosis in human neuroblastoma cells. Cell Death Differ. 1994; 1: 85–92.[Medline] [Order article via Infotrieve]
15.
Taylor D, Badiani P, Weston K. A dominant negative interfering myb mutant causes apoptosis in T cells. Genes Dev. 1996; 10: 2732–2744.
16.
Salomni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity, Proc Natl Acad Sci U S A. 1997; 94: 3296–3301.
17. Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, Whitehead RH, Ramsay RG. c-myb downregulation is associated with human colon cell differentiation, apoptosis and decreased Bcl-2 expression. Cancer Res. 1998 58; 5168–5175.[Medline] [Order article via Infotrieve]
18.
Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, Dsouza S, Farrell CL, Plow EF, Levy RJ, Dicorleto PE, Topol EJ. Effects of antisense c-myb oligonucleotides on vascular smooth-muscle cell-proliferation and response to vessel wall injury Circ Res. 1995; 76: 505–513.
19.
Gunn J, Holt CM, Francis SE, Shepherd L, Grohmann M, Crossman DC, Cumberland DC. The effect of oligonucleotides to c-myb inhibits vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res. 1997; 80: 520–531.
20.
Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb ODNs suppress smooth muscle cell proliferation in vitro. Circ Res. 1992; 70: 835–843.
21. Simons M, Edelman ER, Dekeyser JL, Langer R, Rosenberg RD. Antisense c-myb ODNs inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992; 359: 67–70.[Medline] [Order article via Infotrieve]
22. Azrin MA, Mitchel JF, Bow LM, Pedersen CA, Cartun RW, Aretz TH, Waters DD, McKay RG. Local delivery of c-myb antisense oligonucleotides during balloon angioplasty. Cathet Cardiovasc Diagn. 1997; 41: 232–240.[Medline] [Order article via Infotrieve]
23.
Evan G, Littlewood T. A matter of life and cell death. Science. 1998; 281: 1317–1322.
24. Schmitt JF, Keogh M-C, Dennehey U, Chen D, Weston K, Taylor D, Kakkar VV, Lemoine NR. Tissue-selective expression of dominant-negative proteins for the regulation of vascular smooth muscle cell proliferation. Gene Ther. 1999; 6: 1184–1191.[Medline] [Order article via Infotrieve]
25.
Shi Y, Pieniek M, Fard A, O’Brien J, Mannion J, Zalewski A. Adventitial remodelling after coronary arterial injury. Circulation. 1996; 93: 340–348.
26. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992; 19: 267–274.[Abstract]
27.
Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1ß in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996; 16: 1000–1006.
28.
Patel S, Shi Y, Niculescu R, Chung EH, Martin JL, Zalewski A. Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation. 2000; 101: 524–532.
29.
Pollman MJ, Naumovski L, Gibbons GH. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-ß1 in endothelial cells versus smooth muscle cells. Circulation. 1999; 99: 2019–2026.
30. Pollman MJ, Hall JL, Mann MJ, Zhangh L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 1998; 4: 222–227.[Medline] [Order article via Infotrieve]
31. Kutryk MJB, Serruys PW, Bruining N, Sabate M, Ligthart J, van den Brand M, Hamburger JN, van der Giessen WJ, Foley DP, de Feyter PJ. Randomized trial of antisense oligonucleotide against c-myc for the prevention of restenosis after stenting: results of the Thoraxcenter "ITALICS" trial. Eur Heart J. 1998; 19S: 569.Abstract.
32. Noguchi K, Yamana H, Kitanaka C, Mochizuki T, Kokubu A, Kuchino Y. Differential role of the JNK and p38 MAPK pathway in c-myc and s-myc mediated apoptosis. Biochem Biophys Res Commun. 1999; 267: 221–227.
33. Bennett MR, Evans GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995; 95: 2266–2274.[Medline] [Order article via Infotrieve]
34.
Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res. 2000; 45: 736–746.
35. Helene C, Toulme J-J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990; 1049: 99–125.[Medline] [Order article via Infotrieve]
36.
Christen T, Bochaton-Piallat ML, Neuville P, Rensen S, Redard M, van Eys G, Gabbiani G. Cultured porcine coronary artery smooth muscle cells: a new model with advance differentiation. Circ Res. 1999; 85: 99–107.
37.
Slomp J, Gittenberger-de Groot AC, Glukhova MA, van Munsteren C, Kockx MM, Schwartz SM, Koteliansky VE. Differentiation, dedifferentiation, and apoptosis of smooth muscle cells during the development of the human ductus arteriosus. Arterioscler Thromb Vasc Biol. 1997; 17: 1003–1009.
38.
Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell-surface receptors and remove it from low-affinity binding sites on extracellular matrix. J Biol Chem. 1995; 270: 2620–2627.
This article has been cited by other articles:
 |
|
 |
|
  J. Cornelissen, J. Armstrong, and C. M. Holt Mechanical Stretch Induces Phosphorylation of p38-MAPK and Apoptosis in Human Saphenous Vein Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 451 - 456. [Abstract] [Full Text]
|
|
|
|
 |
|
 X.-M. You, I. N. Mungrue, W. Kalair, T. Afroze, B. Ravi, A. M. Sadi, R. Gros, and M. Husain Conditional Expression of a Dominant-Negative c-Myb in Vascular Smooth Muscle Cells Inhibits Arterial Remodeling After Injury Circ. Res., February 21, 2003; 92(3): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Jiang, C. Petrovas, and G. E. Sonenshein RelB-p50 NF-{kappa}B Complexes Are Selectively Induced by Cytomegalovirus Immediate-Early Protein 1: Differential Regulation of Bcl-xL Promoter Activity by NF-{kappa}B Family Members J. Virol., May 3, 2002; 76(11): 5737 - 5747. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||